Conclusions
The occurrence of probable re-infection with SARS-CoV-2 in our
population seemed to be an uncommon occurrence that was associated with
mild symptomatology at the time of their primary infection. Our data
does support the CDC’s recommendation that testing for SARS-CoV-2
re-infection is not needed prior to 90 days after symptoms arise.
References:
1. Chen W, Hu Z, Yi C, et al. An unusual COVID-19 case with over four
months of viral shedding in the presence of low neutralizing antibodies:
a case report. J Biomed Res . 2020;34(6):470.
doi:10.7555/jbr.34.20200099
2. To KK-W, Hung IF-N, Ip JD, et al. Coronavirus Disease 2019 (COVID-19)
Re-infection by a Phylogenetically Distinct Severe Acute Respiratory
Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing.Clin Infect Dis . August 2020. doi:10.1093/cid/ciaa1275
3. Colson P, Finaud M, Levy N, Lagier JC, Raoult D. Evidence of
SARS-CoV-2 re-infection with a different genotype. J Infect .
2020. doi:10.1016/j.jinf.2020.11.011
4. Overview of Testing for SARS-CoV-2 (COVID-19) | CDC.Natl Cent Immun Respir Dis (NCIRD), Div Viral Dis . 2020.
https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html.
Accessed December 9, 2020.
5. Duration of Isolation and Precautions for Adults with COVID-19
| CDC.
https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html.
Published 2020. Accessed December 9, 2020.
6. Huang J, Zheng L, Li Z, et al. Kinetics of SARS-CoV-2 positivity of
infected and recovered patients from a single center. Sci Rep .
2020;10(1). doi:10.1038/s41598-020-75629-x
7. Madhi SA, Polack FP, Piedra PA, et al. Respiratory Syncytial Virus
Vaccination during Pregnancy and Effects in Infants. N Engl J
Med . 2020;383(5):426-439. doi:10.1056/NEJMoa1908380
8. Wang J, Hang X, Wei B, et al. Persistent SARS-COV-2 RNA positivity in
a patient for 92 days after disease onset: A case report. Medicine
(Baltimore) . 2020;99(34):e21865. doi:10.1097/MD.0000000000021865
9. Avadhanula V, Nicholson E, Ferlic-Stark L, et al. Viral load of
SARS-CoV-2 in adults during the first and second wave of COVID-19
pandemic in Houston, TX: the potential of the super-spreader. J
Infect Dis . 2021;(Accepted).
10. Liang C, Cao JT, Liu Z, et al. Positive RT-PCR test results after
consecutively negative results in patients with COVID-19. Infect
Dis (Auckl) . 2020;52(7):517-519. doi:10.1080/23744235.2020.1755447
11. Bongiovanni M, Basile F. Re-infection by COVID-19: a real threat for
the future management of pandemia? Infect Dis (Auckl) .
2020;52(8):581-582. doi:10.1080/23744235.2020.1769177
12. Tomassini S, Kotecha D, Bird PW, Folwell A, Biju S, Tang JW. Setting
the criteria for SARS-CoV-2 reinfection – six possible cases. J
Infect . 2020. doi:10.1016/j.jinf.2020.08.011
13. Keech C, Albert G, Cho I, et al. Phase 1–2 Trial of a SARS-CoV-2
Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med .
2020;383(24):2320-2332. doi:10.1056/nejmoa2026920
14. Chan PKS, Lui G, Hachim A, et al. Serologic Responses in Healthy
Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020. Emerg
Infect Dis . 2020;26(12):3076-3078. doi:10.3201/eid2612.203833
15. Zhang F, Gan R, Zhen Z, et al. Adaptive immune responses to
SARS-CoV-2 infection in severe versus mild individuals. Signal
Transduct Target Ther . 2020;5(1):156. doi:10.1038/s41392-020-00263-y